Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 6Ovarian Neoplasms 4Neoplasms 3Endometrial Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × AZD5305 × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

AstraZeneca

Phase 1 Active not recruiting
354 enrolled
Gynecologic

Ovarian Neoplasms

NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡